iSpecimen expands research on COVID-19 with sequencing samples to detect variants


What you should know:

iSpecimen, the developer of an online marketplace that connects human biospecimen with researchers, announced that it has expanded its vendor capabilities in support of COVID-19[feminine[feminine researchers.

– Through a new partnership with a reference laboratory in New York, researchers seeking to validate their own assays for identifying COVID variants can obtain sequential and non-sequenced positive and negative COVID-19 swabs on various media using iSpecimen. This lab is sequencing the latest swabs to identify new variants of COVID-19 as the virus continues to progress globally.

Supporting more than 200 projects related to COVID-19

iSpecimen has been working diligently with the research community to understand COVID-19. In early 2020, iSpecimen began sending serum samples to the U.S. Centers for Disease Control and Prevention (“CDC”) to help researchers monitor the development of antibodies for possible immunity targeting. iSpecimen provided the CDC with 600 positive serum samples for SARS-CoV-2 and 100 negative serum samples. In addition, iSpecimen has provided other federal agencies and private companies with custom collections of COVID-19, which are often complex and complement the most immediate availability of residual or bank samples. In total, iSpecimen has delivered more than 15,000 copies for more than 200 COVID-related projects since the start of the pandemic.

Source link